In times of increasing environmental problems, increasing population numbers and the associated difficulties in feeding people adequately while maintaining health, we have made it our task to reduce one of the many potential risks to human and enviromental well-being.
Worldwide rat plagues are a problem that many still underestimate. Rats are carriers of disease, destroy crops or even entire ecosystems. Currently, there is no environmentally friendly solution and the rodents are developing resistance to the existing substances. We want to finally combat those challenges.
A new (third) generation of anticoagulant rodenticides
This new generation of anticoagulant rodenticide is devoid of all the shortcomings of the 1st- and 2nd generation. They mark a sensational advancement in rat control.
New oraly active anticoagulant substances (coumarins, NOACs) have been developed for anticoagulant therapy in human medicine in recent years. Such NOACs are progressively replacing coumarins in thrombosis prevention. In contrast to coumarins (which prevent blood coagulation by inhibition of Vitamin K and the synthesis of multiple coagulation factors) such NOACs inhibit activated coagulation factors in a 1 : 1 ratio. These new substances have been exclusively used for therapeutic uses in human medicine and therefore have gained patent protection exclusively for therapeutic use in humans. We have filed patent claims for the use of such agents for use in rodents.
Since coagulation in mammals and birds share the same type of cascading activation processes these substances are also actively inhibiting blood coagulation in pests like rats. Basing on the inhibition of coagulation factors, the mechanism of action of NOACs, similar to conventional Vitamin K antagonistic rodenticides, includes a delay phase between ingestion and lethal action of 12 hours up to several days. This delay is essential in order to make it impossible for the rats to connect the ingestion of the bait to the death of fellow rats. Such a delayed mode of action is therefore of utmost importance since rats, finding new food sources, will always send out one (or more) fellow rat(s) as a “food taster” to test the compatibility of such food, and fellow rats of this tribe will not start feeding from that very food source until the taster has survived for at least a day after bait-ingestion.
The effect of our 3rd generation of rodenticide, in contrast to the conventional Vitamin K antagonist-based classical rodenticides, is based on the direct 1 : 1 molecular interaction with one or more of the coagulation factors, which makes the generation of resistance to such an agent highly unlikely. Simultaneously, the degradability of such agents and the lack of environmental persistence marks further major and decisive advantages in comparison to conventional 2nd generation rodenticides. Furthermore, when bait boxes become leaky and the rodenticide leaks into the environment or into water, the new generation rodenticides are rapidly diluted and washed away as they become rapidly degraded in the environment. After ingestion by the target animal (rats) the 3rd generation compound rodenticides become rapidly metabolized and hence progressively lose any cross toxicity to predators and scavengers. Contamination of earth, waters or other animals is thus reliably prevented.
Future possibilities include the better species-(rat)-selectivity as well as the modulation and optimization of the biological half-life. Together with a partner we also set up a program for the molecular modifications of the specific agents with rational drug design and -selection by detailed screening for further optimization of the properties of the new rodenticides.
The efficacy of our concept of 3rd generation rodenticides has already been proven in a “Proof of Principle” study in wild caught rats.
For further details please also visit our teaser.
Bioroxx GmbH is in search for further investments for the further development of the rodenticide.
If you are interested, please contact us using our contact form or via firstname.lastname@example.org.
We are looking forward to your approach!